Product Description
The research-grade biosimilar is an antibody-drug conjugate that targets Nectin-4, which is highly expressed in urothelial cancers. The original conjugate comprises an anti-Nectin-4 human monoclonal antibody that is chemically linked to a microtubule disrupting drug, monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon internalization in the cell, the MMAE is detached from the antibody due to proteolytic cleavage. The MMAE then disrupts the microtubule network, arrests cell cycle, and induces apoptosis. The original drug conjugate is approved by the FDA to treat metastatic bladder cancer patients, who were previously treated with platinum-containing chemotherapy, or PD-1/PD-L1 checkpoint inhibitors
Biovision | A2176 | Anti-Nectin-4 (Enfortumab Vedotin), Human IgG1 Antibody DataSheet
Antibody Target: Nectin-4
Target Alternative Name: AGS-22CE, AGS-22M, AGS-22M6E, unconjugated:AGS-22C3, AGSM6, LNIR, PRR4, EDSS1, PVRL4
Tag Line: The biosimilar is an antibody-drug conjugate that targets Nectin-4 and induces apoptosis via cell cycle arrest. The original drug conjugate is approved to treat urothelial cancers
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Human Nectin-4
Accession #: DB13007
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE